Background-There is epidemiological evidence that omega-3 polyunsaturated fatty acids (PUFAs) reduce the risk of atrial fibrillation (AF), but clinical data are conflicting. The present study assessed the effects of PUFA on AF in experimental models. Methods and Results-We studied the effects of oral PUFA supplements in 2 experimental AF paradigms: electrical remodeling induced by atrial tachypacing (400 bpm for 1 week) and congestive heart failure-associated structural remodeling induced by ventricular tachypacing (240 bpm for 2 weeks). PUFA pretreatment did not directly change atrial effective refractory period (128Ϯ6 [meanϮSEM] versus 127Ϯ2 ms; all effective refractory periods at 300-ms cycle lengths) or burst pacing-induced AF duration (5Ϯ4 versus 34Ϯ18 seconds). Atrial tachypacing dogs had shorter refractory periods (73Ϯ6 ms) and greater AF duration (1185Ϯ300 seconds) than shams (119Ϯ5 ms and 20Ϯ11 seconds; PϽ0.01 for each). PUFAs did not significantly alter atrial tachypacing effects on refractory periods (77Ϯ8 ms) or AF duration (1128Ϯ412 seconds). PUFAs suppressed ventricular tachypacing-induced increases in AF duration (952Ϯ221 versus 318Ϯ249 seconds; PϽ0.05) and attenuated congestive heart failure-related atrial fibrosis (from 19.2Ϯ1.1% to 5.8Ϯ1.0%; PϽ0.001) and conduction abnormalities. PUFAs also attenuated ventricular tachypacing-induced hemodynamic dysfunction (eg, left ventricular end-diastolic and left atrial pressure from 12.2Ϯ0.5 and 11.4Ϯ0.6 mm Hg, respectively, to 6.4Ϯ0.5 and 7.0Ϯ0.8 mm Hg; PϽ0.01) and phosphorylation of mitogen-activated protein kinases (extracellular-signal related and P38 kinase).
Conclusions-PUFAs